Is this the main takeaway from BOM?

“Given the large body of preclinical human studies as well as a suggestion of the effects on heart failure and subgroups and the concordance of nonsignificant effects across the secondary endpoints, there is cautious optimism for this drug,” said Shah. “While it's not ready for use in patients, I would say that these results suggest that an adequately powered clinical trial is needed.”

This trial should be larger and potentially focus on “higher-risk subgroups, such as patients with heart failure or patients with chronic kidney disease,” Shah advised.

Koo